Cargando…

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype

Hereditary tyrosinemia type 1 (HT1) is a genetic disorder of the tyrosine degradation pathway (TIMD) with unmet therapeutic needs. HT1 patients are unable to fully break down the amino acid tyrosine due to a deficient fumarylacetoacetate hydrolase (FAH) enzyme and, therefore, accumulate toxic tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neuckermans, Jessie, Lequeue, Sien, Claes, Paul, Heymans, Anja, Hughes, Juliette H., Colemonts-Vroninks, Haaike, Marcélis, Lionel, Casimir, Georges, Goyens, Philippe, Martens, Geert A., Gallagher, James A., Vanhaecke, Tamara, Bou-Gharios, George, De Kock, Joery
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047938/ https://www.ncbi.nlm.nih.gov/pubmed/36980965 http://dx.doi.org/10.3390/genes14030693

Ejemplares similares

Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation
por: Colemonts-Vroninks, Haaike, et al.
Publicado: (2020)

Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways
por: Haaike, Colemonts-Vroninks, et al.
Publicado: (2022)

A robust bacterial high-throughput screening system to evaluate single nucleotide polymorphisms of human homogentisate 1,2-dioxygenase in the context of alkaptonuria
por: Lequeue, Sien, et al.
Publicado: (2022)

Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells
por: De Kock, Joery, et al.
Publicado: (2020)

High-throughput quantification of ochronotic pigment formation in Escherichia coli to evaluate the potency of human 4-hydroxyphenylpyruvate dioxygenase inhibitors in multi-well format
por: Neuckermans, Jessie, et al.
Publicado: (2020)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019)

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017)

Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
por: García, María Ignacia, et al.
Publicado: (2017)

Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
por: Jack, Rhona M., et al.
Publicado: (2019)

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review
por: Geppert, Julia, et al.
Publicado: (2017)

A robust bacterial assay for high-throughput screening of human 4-hydroxyphenylpyruvate dioxygenase inhibitors
por: Neuckermans, Jessie, et al.
Publicado: (2019)

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1
por: Guffon, Nathalie, et al.
Publicado: (2017)

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
por: Ranganath, L.R., et al.
Publicado: (2022)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
por: Ooi, Nicola, et al.
Publicado: (2023)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

The Discovery of the Mode of Action of Nitisinone
por: Lock, Edward A.
Publicado: (2022)

Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
por: Norman, Brendan P., et al.
Publicado: (2022)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, A. S., et al.
Publicado: (2019)

Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls
por: van Ginkel, Willem G., et al.
Publicado: (2016)

Correction to: Assessing the effect of nitisinone induced hypertyrosinaemia on monoamine neurotransmitters in brain tissue from a murine model of alkaptonuria using mass spectrometry imaging
por: Davison, Andrew S., et al.
Publicado: (2019)

Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
por: Boeckmans, Joost, et al.
Publicado: (2022)

In Vitro Differentiation of Embryonic and Adult Stem Cells into Hepatocytes: State of the Art
por: Snykers, Sarah, et al.
Publicado: (2009)

Current Status of Human Adipose–Derived Stem Cells: Differentiation into Hepatocyte-Like Cells
por: Al Battah, Feras, et al.
Publicado: (2011)

Syndrome of hereditary tyrosinemia in mink
por: Christensen, K, et al.
Publicado: (1978)

Large‐Scale Production of LGR5‐Positive Bipotential Human Liver Stem Cells
por: Schneeberger, Kerstin, et al.
Publicado: (2020)

Uncorrected refractive errors
por: Naidoo, Kovin S, et al.
Publicado: (2012)

Genetic and Epigenetic Modification of Rat Liver Progenitor Cells via HNF4α Transduction and 5’ Azacytidine Treatment: An Integrated miRNA and mRNA Expression Profile Analysis
por: Bolleyn, Jennifer, et al.
Publicado: (2020)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Electronic structure and molecular properties of nitisinone and mesotrione in water
por: Imrich, Richard, et al.
Publicado: (2023)

Comment on Pancreatitis in Type 1 Tyrosinemia
por: Rahmoune, Hakim, et al.
Publicado: (2017)

Tyrosinemia type III in an asymptomatic girl
por: Szymanska, Edyta, et al.
Publicado: (2015)

The uncorrected refractive error challenge
por: Naidoo, Kovin, et al.
Publicado: (2014)

Uncorrected Errors of Refraction and Their Results
por: Buchanan, Leslie
Publicado: (1899)

Cannot write session to /tmp/vufind_sessions/sess_ms1stn5if3v6d53q21vm0i2tee